Analysts expect Cytosorbents Corp (NASDAQ:CTSO) to report ($0.10) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cytosorbents’ earnings, with estimates ranging from ($0.14) to ($0.07). Cytosorbents posted earnings per share of ($0.16) in the same quarter last year, which indicates a positive year-over-year growth rate of 37.5%. The company is scheduled to report its next quarterly earnings report on Friday, March 2nd.
According to Zacks, analysts expect that Cytosorbents will report full year earnings of ($0.26) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.23). For the next fiscal year, analysts forecast that the business will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.45) to ($0.35). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). Cytosorbents had a negative return on equity of 233.72% and a negative net margin of 67.83%.
Cytosorbents (NASDAQ:CTSO) traded up $0.10 during midday trading on Monday, reaching $7.70. The company’s stock had a trading volume of 92,893 shares, compared to its average volume of 137,910. The stock has a market cap of $218.05, a PE ratio of -24.06 and a beta of -0.54. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17. Cytosorbents has a fifty-two week low of $3.30 and a fifty-two week high of $7.90.
In related news, CFO Kathleen P. Bloch sold 12,400 shares of the business’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $7.75, for a total transaction of $96,100.00. Following the completion of the transaction, the chief financial officer now owns 241,038 shares in the company, valued at approximately $1,868,044.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Vincent Capponi sold 4,000 shares of the business’s stock in a transaction on Monday, November 27th. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the transaction, the chief operating officer now owns 271,062 shares of the company’s stock, valued at approximately $1,897,434. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,800 shares of company stock valued at $360,620. Company insiders own 5.60% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Skylands Capital LLC boosted its holdings in Cytosorbents by 45.1% during the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after acquiring an additional 225,558 shares during the period. Wealthcare Advisory Partners LLC purchased a new position in Cytosorbents during the 3rd quarter valued at $365,000. Fortaleza Asset Management Inc. raised its position in Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 10,500 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after purchasing an additional 22,500 shares in the last quarter. Institutional investors own 9.47% of the company’s stock.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.